Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trialYung‐Jue Bang, Narikazu Boku, Rui‐Hua Xu et al.|The Lancet Oncology|2017Cited by 291
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Tanios Bekaii‐Saab, Danny Nguyen et al.|Journal of Clinical Oncology|2023Cited by 100
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyNehal J. Lakhani, Wells A. Messersmith, Laura Q.M. Chow et al.|Seoul National University Open Repository (Seoul National University)|2021Cited by 95
Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancerSang‐A Kim, Keun‐Wook Lee|Scientific Reports|2021Cited by 20
AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)Koung Jin Suh, Keun‐Wook Lee|The Oncologist|2023Cited by 19